Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future—An Industry View

The COVID-19 pandemic caused considerable disruption to the development, regulatory evaluation, production, and distribution of medicinal products. Key healthcare stakeholders were under pressure to develop and review medicinal products to address the health emergency, while preserving the continuit...

Descripción completa

Detalles Bibliográficos
Autores principales: Geraci, Gaia, Bernat, Janis, Rodier, Céline, Acha, Virginia, Acquah, Jaqueline, Beakes-Read, Ginny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237066/
https://www.ncbi.nlm.nih.gov/pubmed/37266868
http://dx.doi.org/10.1007/s43441-023-00536-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237066/
https://www.ncbi.nlm.nih.gov/pubmed/37266868
http://dx.doi.org/10.1007/s43441-023-00536-y

Ejemplares similares